Table 2.

Time to Evaluation and Predictors of Being Evaluated for Hepatitis C Virus

Covariate	n (%)	Median time to evaluation (years) (interquartile range)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Age
<40 years old	110 (44)	3.12 (1.78–4.86)	Ref
≥40 years old	138 (56)	2.88 (1.57–5.48)	1.01 (0.98–1.04)
Gender
Female	52 (21)	3.25 (2.04–4.66)	Ref
Male	196 (79)	2.94 (1.40–5.12)	1.02 (0.68–1.52)
Race/Ethnicity (%)
White	158 (64)	2.88 (1.40–4.76)	Ref	Ref
African American	59 (24)	4.16 (1.79–5.54)	0.66 (0.44–0.99)	0.68 (0.45–1.02)
Hispanic	20 (8)	3.58 (2.03–4.78)	0.75 (0.43–1.30)	0.80 (0.45–1.41)
Alaska Native/American Indian	11 (4)	2.26 (1.15–n/a)	1.25 (0.45–3.42)	1.35 (0.49–3.74)
CD4 cell count (cells/μL)a
≥200	141 (57)	2.70 (1.65–4.71)	Ref	Ref
<200	106 (43)	3.79 (1.34–5.39)	0.81 (0.58–1.13)	0.83 (0.58–1.18)
HIV RNA level (copies/mL)b
<500	75 (30)	3.47 (1.65–4.45)	Ref
500–10,000	55 (22)	3.47 (1.57–5.33)	0.89 (0.52–1.51)
>10,000	117 (47)	2.77 (1.58–5.17)	0.93 (0.59–1.46)
Antiretroviral therapyc
No	160 (65)	2.84 (1.57–5.12)	Ref
Yes	85 (35)	3.51 (1.86–4.90)	0.84 (0.56–1.26)
History of substance abuse
No	62 (25)	3.68 (1.33–5.20)	Ref
Yes	186 (75)	2.88 (1.61–4.97)	0.99 (0.67–1.42)
History of mental health diagnosis
No	124 (50)	2.77 (1.61–4.65)	Ref
Yes	124 (50)	3.49 (1.51–5.17)	1.04 (0.74–1.46)

^aNadir CD4 count considered at time of first HCV RNA test, data not available for 1 patient.

^bMost recent HIV RNA test considered at time of first HCV RNA test. Data available within 6 months for 201/248 (83%) of patients. Data not available for 1 patient.

^cOn highly active antiretroviral therapy within 6 months of first HCV RNA test; data not available for 3 patients.

n/a, not available; HCV, hepatitis C virus.